Tamara K Berthoud
Overview
Explore the profile of Tamara K Berthoud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
743
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berthoud T, Ahmed T, Nadia W, Petrov I, Yang L, Colledge D, et al.
Vaccine
. 2024 Nov;
43(Pt 2):126513.
PMID: 39536477
PreHevbrio® is a 3-antigen HBV vaccine (3-A-HBV) engineered to express the three HBV envelope proteins; the small 'S' hepatitis B surface antigen (SHBs or HBsAg), the middle pre-S2 + HBsAg...
2.
Barros P, Berthoud T, Aloufi N, Angel J
Immunotargets Ther
. 2021 Mar;
10:47-62.
PMID: 33728276
Soluble cytokine receptors can influence immune responses by modulating the biological functions of their respective ligands. These effects can be either agonistic or antagonistic and a number of soluble cytokine...
3.
Cote S, Burke Schinkel S, Berthoud T, Barros P, Sanchez-Vidales M, Davidson A, et al.
Eur J Immunol
. 2020 May;
50(10):1537-1549.
PMID: 32390135
The IL-7 receptor specific α chain, CD127, can be expressed both as a membrane-associated (mCD127) and a soluble form (sCD127), however, the mechanisms involved in their regulation remain to be...
4.
Cote S, Stilla A, Burke Schinkel S, Berthoud T, Angel J
AIDS
. 2019 Apr;
33(6):985-991.
PMID: 30946152
Objectives: Th17 cells are key regulators of functional immunity in mucosal tissues, including the gut-associated lymphoid tissue (GALT), an important site of immune impairment in HIV infection. During HIV infection,...
5.
Fernandes J, Berthoud T, Kumar A, Angel J
PLoS One
. 2017 Nov;
12(11):e0186823.
PMID: 29091911
Objectives: HIV infection causes a profound depletion of gut derived Th17 cells, contributing to loss of mucosal barrier function and an increase in microbial translocation, thus driving systemic immune activation....
6.
Antrobus R, Coughlan L, Berthoud T, Dicks M, Hill A, Lambe T, et al.
Mol Ther
. 2013 Dec;
22(3):668-674.
PMID: 24374965
Adenoviruses are potent vectors for inducing and boosting cellular immunity to encoded recombinant antigens. However, the widespread seroprevalence of neutralizing antibodies to common human adenovirus serotypes limits their use. Simian...
7.
Antrobus R, Berthoud T, Mullarkey C, Hoschler K, Coughlan L, Zambon M, et al.
Mol Ther
. 2013 Jul;
22(1):233-8.
PMID: 23831594
Current seasonal influenza vaccines have reduced immunogenicity and are of suboptimal efficacy in older adults. We have previously shown that the novel candidate vaccine MVA-NP+M1 is able to boost memory...
8.
Powell T, Peng Y, Berthoud T, Blais M, Lillie P, Hill A, et al.
PLoS One
. 2013 May;
8(5):e62778.
PMID: 23658773
Current influenza vaccines stimulate neutralising antibody to the haemagglutinin antigen but as there is antigenic drift in HA it is difficult to prepare a vaccine in advance against an emergent...
9.
Antrobus R, Lillie P, Berthoud T, Spencer A, McLaren J, Ladell K, et al.
PLoS One
. 2012 Nov;
7(10):e48322.
PMID: 23118984
Background: Current influenza vaccines have reduced immunogenicity and are of uncertain efficacy in older adults. We assessed the safety and immunogenicity of MVA-NP+M1, a viral-vectored influenza vaccine designed to boost...
10.
Lillie P, Berthoud T, Powell T, Lambe T, Mullarkey C, Spencer A, et al.
Clin Infect Dis
. 2012 Mar;
55(1):19-25.
PMID: 22441650
Background: The novel influenza vaccine MVA-NP+M1 is designed to boost cross-reactive T-cell responses to internal antigens of the influenza A virus that are conserved across all subtypes, providing protection against...